STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #489 by analyst upside · 2026-08-13
PHAR
Pharming Group N.V.
Healthcare · Market Cap $837M · P/E 84.5x
ANALYST PRICE TARGET
+190.4%
implied upside to consensus target
Current Price $11.83
Consensus Target $34.35
Bull Target $39.0
Bear Target $23.4
Analysts Covering 4
ANALYST CONSENSUS - BUY
Strong Buy
0
Buy
4
Hold
0
Sell
0
52-Week Low $9.62
52-Week High $21.34
YTD Return -31.0%
FUNDAMENTALS
Market Cap $837M
P/E Ratio (TTM) 84.5x
Forward P/E 38.5x
EPS (TTM) $0.14
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $366M
Profit Margin 2.5%
52-WEEK RANGE
52-Week Low $9.62
52-Week High $21.34
Current Price $11.83
Bear Target $23.4
Bull Target $39.0
● Now $11.83 ● Target $34.35
TRADING DATA
Avg Volume 12K
YTD Return -31.0%
Analyst Count 4
Consensus Buy
Upside to Target +190.4%
Last Updated 2026-08-13

ANALYST SUMMARY

Pharming Group N.V. (PHAR) is currently trading at $11.83 with a Wall Street consensus price target of $34.35, implying potential upside of 190.4% over the next 12 months. 4 analysts currently cover PHAR, with a consensus rating of Buy - 100% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $39.0, while the most cautious has a target of $23.4.

PHAR operates in the Healthcare sector with a market capitalisation of $837M. The stock is down 31.0% year-to-date and is currently trading near the lower end of its 52-week range of $9.62 – $21.34.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for PHAR, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Canaccord Genuity ● Initiated
Buy 2026-04-10 Building track record
HC Wainwright & Co. reit
Buy → Buy 2026-03-24 31% win rate (48 calls)
Oppenheimer reit
Outperform → Outperform 2026-03-13 14% win rate (7 calls)
HC Wainwright & Co. reit
Buy → Buy 2025-03-21 31% win rate (48 calls)
HC Wainwright & Co. reit
Buy → Buy 2025-03-20 31% win rate (48 calls)
Oppenheimer - Reiterated
Outperform → Outperform 2025-03-14 14% win rate (7 calls)
HC Wainwright & Co. reit
Buy → Buy 2025-03-14 31% win rate (48 calls)
HC Wainwright & Co. reit
Buy → Buy 2024-12-17 31% win rate (48 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
43
out of 100
Coverage depth
12/30
Consensus clarity
4/30
Vote unanimity
25/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →